Opinion: Injectable peptides are booming across wellness and biohacking circles, but the science and regulatory oversight are struggling to keep pace, writes Dr Sophia Moscovis.
A fast-growing global market has emerged around injectable peptides, fuelled by promising early science, online communities and a growing appetite for “health optimisation”.
I started paying attention when the topic kept coming up casually in conversation. Friends mentioned ordering peptides online to inject at home, with the aim of improving their wellbeing.
As someone who has spent more than 20 years across biomedical research, clinical trials and pharmaceutical drug development, I found myself asking a consistent set of questions. Aren’t these effectively drugs? How are people buying them online? Where is the evidence? And what happens if we are interfering with biological pathways we do not yet fully understand?
The grey market
Wellness and biohacking communities promote peptides, such as BPC-157, TB-500 and GHK-Cu, for tissue repair, skin quality, gut health and hair growth. The underlying science is not trivial. Animal studies show real biological activity, and some of these compounds may eventually prove to have genuine therapeutic value.
But promising biology is not proven clinical benefit. Robust human trial data is limited or absent for most peptides. By contrast, GLP-1 receptor agonists, the peptide class that includes semaglutide (marketed as Ozempic), underwent extensive randomised controlled trials and long-term safety evaluation before approval. That pathway from preclinical signal to human evidence to regulatory approval exists for good reason. The peptides circulating in the wellness market have not followed it.
Independent testing of grey-market peptides has found significant variability in peptide content versus label claims, endotoxin contamination from poor manufacturing conditions, and in some cases, entirely wrong compounds in the vial.
Furthermore, many Australians purchase peptides from overseas suppliers, operating outside established regulatory frameworks. They arrive in clinical-looking vials but have not undergone the manufacturing and quality controls required of approved medicines. Physicians in integrative or longevity-focused practices also prescribe peptides, which compounding pharmacies then dispense. Both approaches rely on limited evidence.
According to ACS Peptide Testing Labs, 17 per cent of peptide samples they analysed contained detectable levels of heavy metals including lead, cadmium and mercury. While a self-selected sample, the finding highlights that the danger includes what else may be in the vial, as well as the compounds themselves.
The biology of the peptides also draws my attention. Several widely used peptides promote angiogenesis, the formation of new blood vessels, which is central to their appeal for tissue repair. But angiogenesis is also how tumours sustain themselves and metastasise.
This does not mean these peptides cause cancer. But within any large population using these compounds, some will have early undiagnosed malignancies. Whether pro-angiogenic peptides could accelerate progression in those individuals has not been studied.
A deep distrust of pharmaceuticals
Australia has a well-established framework for therapeutic goods. Promotional claims for approved drugs must be evidence-based and not directed at consumers, and the TGA enforces this rigorously.
A parallel system has quietly taken shape alongside it. Social media influencers promote peptides, overseas suppliers sell them without therapeutic goods registration, and some clinicians operating at the frontier of conventional practice prescribe them.
There is also a cultural shift worth acknowledging. Researchers evaluated the Covid-19 vaccines through large randomised controlled trials with structured safety monitoring. Yet for many people, that evidence base was insufficient.
Interestingly, some of those same people are now injecting peptides supported primarily by animal studies and online testimonials. The pandemic deepened an existing distrust of pharmaceutical institutions, but many people are now channelling that distrust toward alternatives outside the regulated system rather than avoiding intervention altogether.
The absence of regulatory oversight, which ought to be a reason for caution, has become for some a signal of authenticity. For those who have spent years feeling dismissed or under-treated within the conventional system, that logic is not difficult to understand. When the side effects of doing nothing are already familiar, an unknown risk feels like a reasonable trade-off.
Back to basics
Thinking back to my conversations with friends, one chat stayed with me. A friend struggling with hair loss following an unsuccessful transplant was researching GHK-Cu before I encouraged him to review his blood work.
His iron had declined significantly across 18 months to a level consistent with clinically significant deficiency, one of the most well-established and treatable causes of hair loss. His physician had seen both results. No investigation was initiated, no supplementation recommended, no connection was made.
He was considering injecting an unregulated compound to address a problem that may have had a straightforward nutritional explanation, which points to a failure in the system rather than the patient.
Anyone considering peptides should start with a comprehensive blood panel tailored to their symptoms, including iron studies, vitamin D, B12, thyroid function, and hormone profiles where relevant. The fundamentals – sleep, diet, physical activity and stress – have evidence bases that substantially exceed those of most commercially available peptides and are worth addressing first.
Making peptides mainstream
The demand driving this market is not going away. For compounds with credible preclinical signals, structured clinical trial pathways could establish where genuine value exists. Supervised access frameworks with mandatory outcome tracking could convert widespread unobserved use into meaningful safety data. Physicians already prescribing these compounds could contribute to the evidence base, but only if the healthcare system establishes mechanisms to capture outcomes and share findings. At present, that infrastructure does not exist.
The approved GLP-1 class demonstrates that peptide therapeutics can deliver real outcomes when properly developed. There is no reason the compounds circulating in the wellness market should remain permanently outside that process.
That space, between possibility and proof, is where the peptide market is expanding fastest. Consumer adoption is moving considerably faster than the evidence. The science may ultimately justify some of these compounds. But right now, most people using them are taking that bet without fully understanding the odds.
Dr Sophia Moscovis is Vice President of Operations and Strategy at Racura Oncology, a clinical-stage biopharmaceutical company developing novel cancer therapeutics. She holds a PhD in Immunology & Genetics and has more than 20 years of experience spanning biomedical research, clinical trials, biotechnology and pharmaceutical drug development.
Want to see more Forbes articles on your feed? Tap here to make Forbes Australia a preferred source on Google.
Look back on the week that was with hand-picked articles from Australia and around the world. Sign up to the Forbes Australia newsletter here or become a member here.
